Furthermore, it was shown in a recent report that Pembrolizumab can be used as a treatment option for PD-L1-positive patients with an already advanced tumor stage and Trastuzumab has been approved as first-line treatment in combination with chemotherapy for HER2/neu-positive patients [69]. Here, ERBB2 is linked to neoplasm.